Fig. 5
From: Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target
Combined use of antibodies targeting PD-1/PD-L1 and FGL1/LAG3 in the tumor microenvironment. The PD-1/P-L1 and FGL1/LAG3 signaling pathways can be inhibited by the corresponding antibodies, leading to the reactivation of nonactive T cells, while downstream pathways and phenotypes associated with tumor cell progression are weakened. In addition to TILs, MDSCs, TAMs (M2) and Tregs in the TME are known to mediate antitumor immunity through the PD-1/PD-L1 pathway, but their roles in the FGL1/LAG3 pathway remain to be determined